Clinical Characteristics and Care Trajectories of Transgender and Gender Diverse Patients With Cancer Seen in a Pediatric Gender Clinic (Q29585): Difference between revisions
Jump to navigation
Jump to search
Superraptor (talk | contribs) (Created a new Item) |
Superraptor (talk | contribs) (Added [en] label: Clinical Characteristics and Care Trajectories of Transgender and Gender Diverse Patients With Cancer Seen in a Pediatric Gender Clinic) |
||
| label / en | label / en | ||
Clinical Characteristics and Care Trajectories of Transgender and Gender Diverse Patients With Cancer Seen in a Pediatric Gender Clinic | |||
Latest revision as of 15:26, 7 November 2024
No description defined
- Clinical Characteristics and Care Trajectories of Transgender and Gender Diverse Patients With Cancer Seen in a Pediatric Gender Clinic.
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Clinical Characteristics and Care Trajectories of Transgender and Gender Diverse Patients With Cancer Seen in a Pediatric Gender Clinic |
No description defined |
|
Statements
There is very little information on the experiences of transgender and gender diverse (TGD) youth with cancer. (English)
BACKGROUND (English)
© 2024 John Wiley & Sons Ltd. (English)
2024
To examine clinical characteristics and care trajectories of TGD youth a history of cancer. (English)
AIMS (English)
© 2024 John Wiley & Sons Ltd. (English)
2024
This case series reviewed records of 2790 pediatric gender clinic patients seen between 2007 and 2022 to identify 14 with a history of cancer diagnosis. (English)
METHODS (English)
© 2024 John Wiley & Sons Ltd. (English)
2024
Demographics, clinical characteristics, disclosure of gender identity to oncology teams, oncology teams' use of correct names and pronouns, documented interprofessional communication between gender health and oncology teams, and course of medical gender affirmation were reviewed. (English)
METHODS (English)
© 2024 John Wiley & Sons Ltd. (English)
2024
Of 14 TGD youth with a history of cancer, 11 (78.6%) were diagnosed prior to presenting to the gender clinic (mean [SD] = 8.2 [4.7] years), three following initial gender care (mean [SD] = 1.1 [0.2] years). (English)
RESULTS (English)
© 2024 John Wiley & Sons Ltd. (English)
2024
Six (42.9%) patients were engaged in annual survivorship care when presenting, and 8 (57.1%) were seen concurrently by both clinics. (English)
RESULTS (English)
© 2024 John Wiley & Sons Ltd. (English)
2024
Nine (64.3%) patients had documented communication between teams. (English)
RESULTS (English)
© 2024 John Wiley & Sons Ltd. (English)
2024
Three-quarters of patients who were seen concurrently by both clinics had documented interprofessional communication. (English)
RESULTS (English)
© 2024 John Wiley & Sons Ltd. (English)
2024
Eight (57.1%) patients received gender affirming hormones, after cancer treatment concluded. (English)
RESULTS (English)
© 2024 John Wiley & Sons Ltd. (English)
2024
TGD youth with cancer experiences present for gender affirming care and merit clinical attention. (English)
CONCLUSION (English)
© 2024 John Wiley & Sons Ltd. (English)
2024
There was variability in (1) patients' and families' disclosure of TGD identities to oncology teams, (2) whether oncology documentation consistently used patients' correct name and pronouns, and (3) whether there was documented interprofessional consultation between teams. (English)
CONCLUSION (English)
© 2024 John Wiley & Sons Ltd. (English)
2024
There is need for ongoing improvement in research and clinical protocols for TGD youth with cancer. (English)
CONCLUSION (English)
© 2024 John Wiley & Sons Ltd. (English)
2024
Madeline H (English)
Bono (English)
MH
Hannah L (English)
Smith (English)
HL
Coleen R (English)
Williams (English)
CR
Kerry (English)
McGregor (English)
K
Ariel K (English)
Berman (English)
AK
6 November 2024
6 November 2024